Valuation: Pharmaniaga

Market Cap 1.4B 344M 302M 285M 260M 487M 33.01B 490M 3.42B 1.32B 16.86B 1.29B 1.27B 54.2B P/E 2026 *
17.7x
P/E 2027 * 15.6x
Enterprise Value 1.4B 344M 302M 285M 260M 487M 33.01B 490M 3.42B 1.32B 16.86B 1.29B 1.27B 54.2B EV / Sales 2026 *
0.34x
EV / Sales 2027 * 0.33x
Free-Float
37.97%
Yield 2026 *
14.3%
Yield 2027 * 19.2%
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Member of Audit Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as A Member of Nomination and Remuneration Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces second Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 13 October 2026 CI
08-13 Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-17 Pharmaniaga Berhad Announces Redesignation of Dato' Dr Faridah Aryani Binti Md Yusof from Member of Risk Committee to Independent and Non Executive Chairman of Risk Committee, Effective 16 July 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Redesignation of Encik Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Director from Alternate Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Chairman of the Risk Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Member of the Nomination and Remuneration Committee, Effective July 1, 2026 CI
06-10 Pharmaniaga Completes 5:1 Share Consolidation MT
05-28 Pharmaniaga says government of Malaysia accepts unit's tender to supply insulin for 3 years RE
05-18 Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 03 July 2026 CI
1 week-3.60%
Current month-7.76%
1 month-10.83%
3 months-10.08%
6 months-14.40%
Current year-24.91%
1 week 1.06
Extreme 1.06
1.11
1 month 1.06
Extreme 1.06
1.21
Current year 1.06
Extreme 1.06
1.7
1 year 1.06
Extreme 1.06
1.7
3 years 0.65
Extreme 0.65
2.35
5 years 0.65
Extreme 0.65
4.4
10 years 0.65
Extreme 0.65
7.25
Manager TitleAgeSince
Chief Executive Officer 53 01/09/2024
Director of Finance/CFO 59 01/06/2012
Chief Administrative Officer 53 01/10/2024
Director TitleAgeSince
Director/Board Member 74 20/07/2022
Director/Board Member 62 01/09/2025
Director/Board Member 53 01/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
3/27/26 A Buy

Director

300,000 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.60%-22.18%-51.91% 343M
-0.31%-0.92%+17.67%+94.13% 101B
-1.08%-2.29%+47.84%+146.86% 51.55B
-0.39%+2.80%-15.18%+261.97% 20.81B
-0.25%-0.87%-11.20%-10.55% 7.93B
-1.66%-0.34%-38.67%-34.93% 6.8B
+3.71%+6.14%-0.79%+19.93% 6.52B
-0.20%-1.00%-19.35%-33.27% 5.93B
+0.30%-0.42%-2.37%+19.12% 4.95B
+1.25%+5.58%+21.00%+23.14% 4.02B
Average +0.17%+0.29%-2.32%+43.45% 21.02B
Weighted average by Cap. -0.32%-0.32%+16.81%+106.29%

Financials

2026 *2027 *
Net sales 4.13B 1.01B 890M 841M 766M 1.43B 97.24B 1.44B 10.06B 3.9B 49.68B 3.81B 3.73B 160B 4.26B 1.05B 918M 867M 790M 1.48B 100B 1.49B 10.37B 4.02B 51.22B 3.93B 3.84B 165B
Net income 93.3M 22.9M 20.1M 18.98M 17.3M 32.38M 2.19B 32.61M 227M 87.97M 1.12B 85.99M 84.13M 3.6B 113M 27.73M 24.33M 22.98M 20.94M 39.2M 2.66B 39.48M 275M 107M 1.36B 104M 102M 4.36B
Net Debt - -
Logo Pharmaniaga
Pharmaniaga Berhad is an investment holding company engaged in the provision of management services to its subsidiaries. The Company’s segments include Manufacturing, Logistics and distribution, and Indonesia. The Manufacturing segment is engaged in manufacturing of pharmaceutical products in Malaysia. The Logistics and distribution segment includes distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Indonesia segment is engaged in manufacturing and distribution of pharmaceutical and medical products in Indonesia. Its product portfolio comprises oral solid dosages, liquid, cream and small volume injectables. It also manufactures general pharmaceuticals, including penicillin, cephalosporin and over-the-counter products. Its research and development capabilities include drug formulation and analytical development, process scale-up, clinical research and product localization.
Employees
3,502
Date Price Change Volume
25/09/26 MYR 1.070 0.00% 1,483,600
24/09/26 MYR 1.070 -0.93% 1,894,300
23/09/26 MYR 1.080 -1.82% 3,622,200
22/09/26 MYR 1.100 0.00% 1,726,800
21/09/26 MYR 1.100 -1.79% 1,175,600
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.070MYR
Average target price
1.530MYR
Spread / Average Target
+42.99%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7081 Stock